Effects of recombinant human thrombopoietin in improving myocardial injury in patients with sepsis

doi:10.3877/cma.j.issn.1674-6902.2020.02.018

Abstract

Abstract:

Objective

To investigate the changes of myocardial injury markers, cardiac functions and inflammatory cytokines in the patients with sepsis treated with recombinant human thrombopoietin (rhTPO), and to determine its effects on the clinical prognosis.

Methods

In this study, the patients with sepsis who met Sepsis 3.0 diagnostic criteria were collected from the Emergency Critical Care Medical Ward of Shanghai First People′s Hospital from January 2016 to April 2019 by retrospective observation method. According to whether they were treated with rhTPO, they were divided into an rhTPO group and a control group. The basic information, clinical data, inflammatory factors, indexes of immune functions, and prognosis conditions were collected. The main monitoring indexes for the patients were the myocardial injury marker Troponin I (TnI) and the cardiac function marker brain natriuretic peptide (BNP). The secondary monitoring indexes were inflammatory cytokines interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α). Student′s t test was employed to treat the normal distribution data, the nonparametric test was employed to treat the abnormal distribution data, and Chi square test or Fisher inspection methods were employed to treat the counting data. And differences between the two groups were compared.

Results

A total of 186 patients with sepsis were included in this study, including 26 patients in the rhTPO group and 160 patients in the control group. On the 7th day of treatment of rhTPO, TnI (0.2517±0.1347 g/L in the rhTPO group vs. 0.6471±0.4145 g/L in the control group, P=0.006), BNP (306.1±53.52 pg/ml in the rhTPO group vs. 529.4±251.1 pg/ml in the control group, P<0.0001), IL-6 (357.1±84.71 pg/ml in the rhTPO group vs. 843.3±514.0 pg/ml in the control group, P<0.0001), and TNF-α (5.850±1.621 pg/ml in the rhTPO group vs. 9.771±9.051 pg/ml in the control group, P<0.0001) showed significant decreases in the patients of the rhTPO group compared with the patients in the control group.

Conclusion

The rhTPO can improve the myocardial injury, the cardiac functions and the inflammatory indexes of sepsis.

Key words: Recombinant human thrombopoietin, Sepsis, Myocardial injury, Cardiac function

Yun Xie, Zhigang Zhou, Rui Tian, Wei Jin, Hui Xie, Jiang Du, Yijun Hou, Xiaolei Teng, Ruilan Wang. Effects of recombinant human thrombopoietin in improving myocardial injury in patients with sepsis[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2020, 13(02): 213-217.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfbjbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-6902.2020.02.018

https://zhfbjbzz.cma-cmc.com.cn/EN/Y2020/V13/I02/213

Figures/Tables 3

References 30

1	Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign：international guidelines for management of sepsis and septic shock: 2016[J]. Crit Care Med, 2017, 43(3): 486-552.
2	Goldenberg NM, Steinberg BE, Slutsky AS, et al. Broken barriers: a new take on sepsis pathogenesis[J]. Science Translational Med, 2011, 3(88): 88ps25-88ps25.
3	Ait-Oufella H, Maury E, Lehoux S, et al. The endothelium: physiological functions and role in microcirculatory failure during severe sepsis[J]. Intens Care Med, 2010, 36(8):1286-1298.
4	Aird WC. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome[J]. Blood, 2003, 101(10): 3765-3777.
5	Hippenstiel S, Suttorp N. Interaction of pathogens with the endothelium[J]. Thromb Haemost, 2003, 89(1): 18-24.
6	Gianfranco B. Endothelial tight junctions: permeable barriers of the vessel wall[J]. Thromb Haemost, 2006, 96(1): 36-42.
7	国家老年疾病临床医学研究中心(解放军总医院)　《感染诱发的老年多器官功能障碍综合征诊治中国专家共识》撰写组. 《感染诱发的老年多器官功能障碍综合征诊治中国专家共识》[J]. 中华老年多器官疾病杂志，2018, 17(1): 3-13.
8	Wu Q, Ren J, Wu X, et al. Recombinant human thrombopoietin improves platelet counts and reduces platelet transfusion possibility among patients with severe sepsis and thrombocytopenia: a prospective study[J]. J Crit Care, 2014, 29(3): 362-366.
9	Zakynthinos SG, Papanikolaou S, Theodoridis T, et al. Sepsis severity is the major determinant of circulating thrombopoietin levels in septic patients[J]. Crit Care Med, 2004, 32(4): 1004.
10	Segre E, Pigozzi L, Lison D, et al. May thrombopoietin be a useful marker of sepsis severity assessment in patients with SIRS entering the emergency department? [J]. Clin Chem Laboratory Med (CCLM), 2014: 1479-1483.
11	Lupia E, Bosco O, Mariano F, et al. Elevated thrombopoietin in plasma of burned patients without and with sepsis enhances platelet activation[J]. J Thromb Haemost, 2010, 7(6): 1000-1008.
12	Nawawi H, Osman NS, Annuar R, et al. Soluble intercellular adhesion molecule-1 and interleukin-6 levels reflect endothelial dysfunction in patients with primary hypercholesterolaemia treated with atorvastatin[J]. Atherosclerosis, 2003, 169(2): 283-291.
13	Tchinda VHM, Tadem AD, Tako EA, et al. Severe malaria in Cameroonian children: correlation between plasma levels of three soluble inducible adhesion molecules and TNF-α[J]. Acta Tropica, 2007, 102(1): 0-28.
14	Kaushansky K. Thrombopoietin[J]. N Engl J Med, 1998, 339(11): 746-754.
15	Van der Meeren A, Mouthon MA, Vandamme M, et al. Combinations of cytokines promote smvival of mice and limit acute aadiation damage in concert with amelioration of vascular damage[J]. Radiat Res, 2004, 161(5): 549-559.
16	Wu Q, Ren J, Wu X, et al. Recombinant human thrombopoietin improves platelet counts and reduces platelet transfusion possibility among patients with severe sepsis and thrombocytopenia: A prospective study[J]. J Crit Care, 2014, 29(3): 362-366.
17	Han JW, Kim KH, Kwun MJ, et al. Suppression of lung inflammation by the ethanol extract of Chung-Sang and the possible role of Nrf2[J]. BMC Complement Al tern Med, 2019, 19(1): 15.
18	Liu Z, Wang Y, Liu Y, et al. Typing of chronic ob structive pulmonary disease using high-resolution computed tomography and the association with smoking, arway inflammation，and common comorbidities[J]. Turk J Med Sci, 2018, 48(5): 945-951.
19	Cardier JE, Dempsey J. Thrombopoietin and its receptor, c-mpl, are constitutively expressed by mouse liver endothelial cells: evidence of thrombopoietin as a growth factor for liver endothelial cells[J]. Blood, 1998, 91(3): 923-929.
20	Stark AK, Sriskantharajah S, Hessel EM, et al. PI3K inhibitors in inflammation, autoimmunity and cancer[J]. Curr Opin Pharmacol, 2015, 23: 82-91.
21	Wang JY, Ye JY, Liang EY, et al. Thrombopoietin Prevents CoCl2-inducing Apoptosis of HUVEC through the PI3K/AKT Pathway[J]. J Exper Hematol, 2018, 26(2): 528.
22	Cheng HW, Chen YF, Wong JM, et al. Cancer cells increase endothelial cell tube formation and survival by activating the PI3K/Akt signalling pathway[J]. J Exper Clin Cancer Res, 2017, 36(1): 27.
23	Ramella R, Gallo MP, Spatola T, et al. A novel role of thrombopoietin as a physiological modulator of coronary flow[J]. Regulatory Peptides, 2011, 167(1): 5-8.
24	Chan KYY, Zhou L, Xiang P, et al. Thrombopoietin improved ventricular function and regulated remodeling genes in a rat model of myocardial infarction[J]. International Journal of Cardiology, 2013, 167(6): 2546-2554.
25	Baker JE, Su J, Koprowski S, et al. Thrombopoietin Receptor Agonists Protect Human Cardiac Myocytes from Injury by Activation of Cell Survival Pathways[J]. Journal of Pharmacology and Experimental Therapeutics, 2015, 352(3): 429-437.
26	Ilva T, Lund J, Porela P, et al. Early markers of myocardial injury: cTnI is enough[J]. Clinica Chimica Acta, 2009, 400(1-2): 0-85.
27	Grybauskiene R, Karciauskaite D, Brazdzionyte J, et al. Brain natriuretic peptide and other cardiac markers predicting left ventricular remodeling and function two years after myocardial infarction[J]. Medicina, 2007, 43(9): 708-715.
28	Singer M, Deutschman CS, Seymour CW, et al. The Third international consensus definitions for sepsis and septic shock (Sepsis-3)[J]. JAMA, 2016, 315(8): 801-810.
29	Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign：international guidelines for management of sepsis and septic shock: 2016[J]. Intensive Care Med, 2017, 43(3): 304-377.
30	Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign：international guidelines for management of severe sepsis and septic shock, 2012[J]. Intensive Care Med, 2013, 39(2): 165-228.

组　别		例数	TnI μg/L	BNP pg/ml	IL-6 pg/ml	TNF-α pg/ml
rhTPO组		26	1.661±4.071	537.9±803.8	1 221±1 896	64.20±77.12
Control组		160	4 465±1.373	415.6±725.5	500.2±961.6	31.45±38.38
	P值		0.170	0.467	0.101	0.398

组　别		例数	TnI μg/L	BNP pg/ml	IL-6 pg/ml	TNF-α pg/ml
rhTPO组		26	1.661±4.071	537.9±803.8	1 221±1 896	64.20±77.12
Control组		160	4 465±1.373	415.6±725.5	500.2±961.6	31.45±38.38
	P值		0.170	0.467	0.101	0.398

[1]	Jin Yang, Xueke Liu, Yuanyuan Zhang, Jun Jin, Yao Wei. Protective effect of gut microbiota-derived lithocholic acid on sepsis-associated hepatic injury [J]. Chinese Journal of Critical Care Medicine(Electronic Edition), 2024, 17(04): 265-274.
[2]	Xia Zhang, Rui Zhang, Zhibo Zheng, Qin Zhang. Shikonin improves prognosis of mice with sepsis-induced cardiomyopathy by modulating lactylation and mitochondrial function [J]. Chinese Journal of Critical Care Medicine(Electronic Edition), 2024, 17(04): 275-284.
[3]	Jingqi Zhang, Yang Jiang, Jialu Sun, Xingzhe Tang, Yufei Zhao, Ying Cui, Xinxiang Li, Jingyue Dai, lin Fu, Xingui Peng. Early identification of sepsis with acute kidney injury by perirenal CT features combined with serum creatinine [J]. Chinese Journal of Critical Care Medicine(Electronic Edition), 2024, 17(04): 285-292.
[4]	Zhenhe Li, Changqing Wei, Guodong Zhen, Zhenfu Li. Changes of serum S1P and Wnt5a in patients with sepsis complicating acute respiratory distress syndrome and their clinical significance [J]. Chinese Journal of Critical Care Medicine(Electronic Edition), 2024, 17(04): 293-300.
[5]	Heng Fan, Min Sun, Jianhua Zhu. Protective effect of salidroside on septic acute kidney injury in rats by inhibiting phosphatidylinositol 3 kinase/protein kinase B/mammalian target of rapamycin signal pathway [J]. Chinese Journal of Critical Care Medicine(Electronic Edition), 2024, 17(03): 188-195.
[6]	Yajuan Jia, Yuming Meng, Zhiwei Gao, Sumin Gao, Jinsong Zhang, Hong Sun. Predictive value of combined detection of platelet to lymphocyte ratio, procalcitonin and interleukin-6 in prognosis of patients with sepsis [J]. Chinese Journal of Critical Care Medicine(Electronic Edition), 2024, 17(02): 118-123.
[7]	Qingying Ke, Yanfei Shen, Qianghong Xu, Guolong Cai. Establishment and validation of a nomogram to predict in-hospital mortality in patients with sepsis-induced cardiomyopathy [J]. Chinese Journal of Critical Care Medicine(Electronic Edition), 2024, 17(01): 10-18.
[8]	Xiaoyu Li, Qing Jiang, Haiqin Tang, Jingzhi Luo. Clinical study of perioperative comprehensive management in ERCP +LC treatment of patients with choledocholithiasis complicated with acute cholangitis [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 57-60.
[9]	Boxing Su, Bo Xiao, Jianxing Li. Hot research and interpretation of surgical therapy for stone disease in the annual meeting of American Urology Association in 2024 [J]. Chinese Journal of Endourology(Electronic Edition), 2024, 18(04): 303-308.
[10]	Zihan Hu, Fei Peng, Qin Sun, Yi Yang. Research progress of extracellular vesicles in vascular endothelial dysfunction in sepsis [J]. Chinese Journal of Critical Care & Intensive Care Medicine(Electronic Edition), 2024, 10(03): 265-270.
[11]	Juanli Liu, Siqing Ma, Wurentana. Research progress of myeloid derived suppressor cells in sepsis [J]. Chinese Journal of Critical Care & Intensive Care Medicine(Electronic Edition), 2024, 10(03): 271-278.
[12]	Shenglin Su, Jinlan Ma, Hongming Yu, Xiaojun Yang. Application of single cell sequencing technology in the study of sepsis immunity [J]. Chinese Journal of Critical Care & Intensive Care Medicine(Electronic Edition), 2024, 10(03): 279-286.
[13]	Mingmin Pang, Meichen Yan, Guangfeng Liu, Jibin Gong, Nana Xu, Yue Zheng, Shaohua Fan, Hao Wang. Progress in fluid resuscitation strategy in septic patients [J]. Chinese Journal of Critical Care & Intensive Care Medicine(Electronic Edition), 2024, 10(02): 189-195.
[14]	Xia Liu, Shuangping Zhao. TDM guided the individualized treatment of polymyxin B in a patient with severe burn sepsis [J]. Chinese Journal of Critical Care & Intensive Care Medicine(Electronic Edition), 2024, 10(01): 85-89.
[15]	Huiying Chen, Minshan Qiu, Hanquan Shao. Construction and application effect of risk factor model for intestinal mucosal barrier function damage induced by sepsis [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2024, 14(05): 448-452.

Please choose a citation manager

Content to export